HOME >> MEDICINE >> NEWS
Twice daily imatinib could improve outcome for people with specific form of gastro-intestinal cancer

This release is also available in German.

Results of a randomised trial in this week's issue of THE LANCET suggest that a single daily 400 mg dose of imatinib--known to be a first-choice treatment for gastro-intestinal stromal tumours (GIST)--is sufficient to induce a therapeutic response; a doubling of a daily dose can slightly improve progression-free survival for patients.

Imatinib is approved worldwide for use in GIST, tumours which do not respond to conventional chemotherapy, which have a prevalence of around 20 per 100,000 population. Jaap Verweij (Erasmus University Medical Center, Netherlands) and colleagues from the European Organisation for Research and Treatment of Cancer (EORTC), the Italian Sarcoma Group (IRG), and the australasian Gastrointestinal Trials Group (AGITG) studied 946 patients with metastatic GIST who were randomly allocated either imatinib 400 mg once or twice a day.

50% of patients receiving two doses of imatinib a day, compared with 56% of patients given a single dose, were alive and free of disease progression at around 2 years follow-up. There was no difference in the proportion of patients (99%) who reported treatment side-effects; the optimum time for therapeutic effect after the start of treatment did not differ between the two groups (around 4 months).

Dr Verweij comments: "If the aim of treatment is response induction, a daily dose of 400 mg given for 46 months seems to be sufficient. However, in patients with widespread metastatic disease, the prolonged progression-free survival achieved with 400 mg twice daily might lead one to favour this regimen. Whether a similar outcome could be achieved with fewer side-effects by making use of the reduction in drug clearance over time--eg, with a starting dose of 400 mg daily followed by stepwise dose escalation to 400 mg twice a day--is still a matter for further clini
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
23-Sep-2004


Page: 1 2

Related medicine news :

1. Study: Among Heart Failure Patients, Women Survive Twice As Long As Men
2. Bullying among sixth graders a daily occurrence, UCLA study finds
3. Current daily smoking may be associated with increased risk for suicidal thoughts and attempts
4. African children with HIV would benefit from daily doses of cheap antibiotic
5. Weekend use matches daily drops for lazy eye
6. New ways identified to treat lazy eye in children: Beyond eye patches and daily drops
7. Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment
8. Study finds once-daily Valcyte prevents serious viral infection after kidney transplant
9. Max daily OTC dose of acetaminophen shows efficacy comparable to Rx doses of naproxen for OA pain
10. New study finds even a small amount of psoriasis can negatively impact daily life
11. OHSU study shows four daily servings of fruits & vegetables reduce breast cancer risk by half

Post Your Comments:
(Date:2/27/2015)... Florida Hospital North Pinellas is being recognized ... Plus hospital. In order to receive the award, Florida ... all Get With The Guidelines - Stroke Quality Achievement ... achieved 75-percent or higher compliance with six of 10 ... are reporting initiatives to measure quality of care. ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 The ... has announced a scholarship for rising freshmen undergraduate students. ... leading periodontist office specializing in many periodontal procedures such ... treatment of gum disease . In honor of ... college scholarship for eligible rising freshmen undergraduate students. ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 ... company that provides vascular, echocardiogram and NCV testing ... be the preferred diagnostic testing provider for young ... coeducational public liberal arts university in Milledgeville, Georgia. ... Wimbledon U collegiate division, include a ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 "After studying the ... the benefits of prenatal spina bifida repair may outweigh the ... 35 to 40 range," says Fetal Care Institute Director ... maternal fetal medicine specialist. "The goal of the study ... for these mothers and their unborn babies." , Studies have ...
(Date:2/27/2015)... New York, NY (PRWEB) February 27, 2015 ... Cole Tickets for his "Forest Hills Drive Tour Act ... third album "2014 Forest Hills Drive" which debuted on the ... selling hip-hop album. In March, this accomplished hip-hop artist ... begins in early March and will visit cities such as ...
Breaking Medicine News(10 mins):Health News:Florida Hospital North Pinellas Receives Get With The Guidelines - Stroke Gold Plus Quality Achievement Award 2Health News:Nashville Periodontist Office AIOH Announces 2015 Scholarship 2Health News:Georgia College Ensures Student-Athletes Are Heart Smart Team Strong; Teams up with Wimbledon Health Partners to Offer Diagnostic Testing 2Health News:Georgia College Ensures Student-Athletes Are Heart Smart Team Strong; Teams up with Wimbledon Health Partners to Offer Diagnostic Testing 3Health News:Pregnant Women with a BMI above 35 Now Eligible for Fetal Spina Bifida Repair Surgery Study at the St. Louis Fetal Care Institute 2Health News:Pregnant Women with a BMI above 35 Now Eligible for Fetal Spina Bifida Repair Surgery Study at the St. Louis Fetal Care Institute 3Health News:J. Cole Tickets in Los Angeles, Mountain View, Chula Vista, New York, Chicago, Indianapolis, Holmdel, Dallas, Seattle, Camden, Bristow, Atlanta, Houston & Detroit On Sale 2Health News:J. Cole Tickets in Los Angeles, Mountain View, Chula Vista, New York, Chicago, Indianapolis, Holmdel, Dallas, Seattle, Camden, Bristow, Atlanta, Houston & Detroit On Sale 3
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
(Date:2/27/2015)... Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... fourth quarter and full year ended December 31, 2014. ... PTC. We are now a growing commercial-stage biopharma company, ... rare disease space," stated Stuart W. Peltz, Ph.D., Chief ... bring the first treatment for Duchenne muscular dystrophy to ...
(Date:2/27/2015)... , Feb. 27, 2015  Chiasma, Inc., a ... product for the orphan condition acromegaly, today announced the ... Participants in the financing included new investors Rock Springs ... public investment fund, as well as existing investors MPM ... ARCH Venture Partners. Chiasma intends to ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
Cached News: